Please assess the completion status of the following clinical trial:

Trial Title: Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with Type II-diabetes mellitus on metformin who are planned to be managed with vildagliptin or glimepiride plus metformin at the time of inclusion.~* Symptomatic Coronary Artery Diseases. (\>30 days).~Exclusion Criteria:~* Hepatic impairment.~* Active malignancy.~* Planned surgical intervention.~* Any signs of hypersensitivity or contraindication to study drugs developed.~* Any patient with any signs of active infection or thrombosis at the time of assessment.~* Addition of any antidiabetic medications or insulin during follows up.~* Chronic inflammatory disease (i.e. inflammatory bowel disease, lupus, inflammatory arthritis, rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection).~* Clinically advanced congestive heart failure - New York Heart Association III-IV~* Severe left ventricular dysfunction (LVEF\<30%) with New York Heart Association II or any New York Heart Association class with documented recent heart failure decompensation (\<3 months)~* Severe stable cardiac angina Community Competence Scale III - IV or Unstable angina~* Pregnancy, lactation or child-bearing potential.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vildagliptin / metformin (Type: EXPERIMENTAL): Group I (n=40) are patients who are taking vildagliptin 50 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.
- glimepiride / metformin. (Type: EXPERIMENTAL): Group II (n=40) are patients who are taking Glimepiride 4 mg oral tablet plus their metformin1000 mg oral tablet to control their blood sugar level.

Based on this trial design, predict the completion outcome and termination type (if applicable).